Teva Pharmaceutical Slips To Loss In Q2, Raises FY26 Revenue Outlook; Stock Up In Pre-Market
Teva Pharmaceutical (TEVA) reported Q2 a net loss of $576 million, or $0.49/share, versus net income of $282 million, or $0.24/share a year earlier. Adjusted earnings were $21 million, or $0.02/share, down from $769 million, or $0.66/share. Revenue fell to $4.142 billion. For FY2026, Teva raised revenue guidance to $16.5-$16.85 billion and expects EPS of 1.91-$2.11.
How this was made
The 30-second read
Why it matters
The combination of a reported net loss and a large decline in adjusted EBITDA contrasts with a modestly improved FY26 revenue outlook, creating a mixed fundamental signal for valuation and positioning.
Market read
Traders can reassess near-term expectations for Teva’s turnaround by balancing weak adjusted profitability against the raised FY26 revenue outlook.
What to watch
The loss is attributed to acquisition-related items (Emalex and ecopipam) and higher taxes, so traders may need to separate one-time acquisition effects from underlying operating momentum.
Background
Teva’s Q2 results include acquisition-related impacts tied to Emalex and ecopipam, alongside weaker generic product revenue.
Ticker impact
Teva reported Q2 net loss of $576M and cut adjusted EBITDA 62%, while raising FY26 revenue outlook to $16.5-$16.85B.
Likely near-term volatility with a bias to stabilize on the raised FY26 revenue outlook, despite weak adjusted profitability.
The article provides both a negative earnings snapshot (loss, lower adjusted EBITDA) and a positive forward guide (higher revenue range), which typically drives mixed tape action rather than a one-direction move.
Market effects
Signals ongoing pressure in generic revenue while innovative products partially offset, consistent with broader branded vs generic mix dynamics in pharma.
Primarily US-listed sentiment for large-cap pharma, with limited direct regional spillover beyond investor positioning in generics-heavy names.
FY26 revenue guidance update can affect global expectations for Teva’s turnaround trajectory and competitive intensity in generics.
Counterpoint
The raised revenue range may not translate into improved profitability, given adjusted EBITDA fell sharply and adjusted EPS remains low.
Key entities
- companyTeva Pharmaceutical Industries Limited
Reported Q2 net loss and adjusted results, and raised FY26 revenue guidance while providing EPS and adjusted EBITDA ranges.
